Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis

Lung Cancer

Volumn 74, Issue 1, 2011, Pages 89-97

  Botrel, Tobias Engel Ayer ^a   Clark, Otávio ^a   Clark, Luciana ^a   Paladini, Luciano ^a   Faleiros, Enéas ^a   Pegoretti, Bruna ^a  

^a Evidencias Consulting   (Brazil)

Author keywords

Bevacizumab; Chemotherapy; Meta analysis; Non small cell lung cancer; Systematic review

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; GEMCITABINE; PACLITAXEL;

ADVANCED CANCER; ANEMIA; ARTICLE; BLEEDING; DRUG EFFICACY; EMBASE; FEBRILE NEUTROPENIA; HEMOPTYSIS; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MEDLINE; META ANALYSIS; METASTASIS; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; VOMITING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG DOSAGE CALCULATIONS; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 80052607351     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.01.028     Document Type: Article

References (35)

1. Toschi L., Cappuzzo F., Jänne P.A. Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer. Ann Oncol 2007, 18(Suppl. (9)):ix150-ix155.
2. Belani C.P., Ramalingam S., Perry M.C., LaRocca R.V., Rinaldi D., Gable P.S., et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 2008, 26(January (3)):468-473.
3. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27(December (36)):6251-6266.
4. Delbaldo C., Michiels S., Syz N., Soria J.C., Le Chevalier T., Pignon J.P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004, 292(July (4)):470-484.
5. Sederholm C., Hillerdal G., Lamberg K., Kolbeck K., Dufmats M., Westberg R., et al. Phase III trial of gemcitabine plus carbplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 2005, 23(November (33)):8380-8388.
6. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(January (2)):92-98.
7. Rajan A., Gutierrez M., Giaccone G. Newer opportunities in systemic therapy of lung cancer. Ann Oncol 2008, 19(Suppl. (7)):vii31-vii37.
8. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374(October (9699)):1432-1440.
9. Genentech: avastin (bevacizumab): full pre-scribing information 2006, Ge-nentech, South San Francisco C.
10. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(December (24)):2542-2550.
11. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22(June (11)):2184-2191.
12. A phase III randomised study of first line bevacizumab combined with cisplatin/gemcitabine (GC) in patients with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC) 2008, European Society of Medical Oncology - ESMO, www.esmo.org/fileadmin/media/presentations/977/613/Manegold%20presentation.ppt.pdf. C. Manegold, Pawel Jv, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh (Eds.).
13. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21(September (9)):1804-1809.
14. Yang K., Wang Y.J., Chen X.R., Chen H.N. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig 2010, 30(4):229-241.
15. Dickersin K., Scherer R., Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994, 309(November (6964)):1286-1291.
16. Clarke M Oxman AD (Eds). Cochrane reviewers handbook 4.1.1. The cochrane library, Issue 4 [updated December 2000]. Oxford: Update Software; 2000.
17. Castro A.A., Clark O.A., Atallah A.N. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. Sao Paulo Med J 1999, 117(May (3)):138-139.
18. Egger M., Smith G.D., Altman D. Systematic reviews in health care 2001, BMJ Books, London.
19. Review Manager (RevMan) [computer program]. Current version: 5.0.24 Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration; 2008 [updated on 16 April 2010].
20. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17(December (24)):2815-2834.
21. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327(September):557-560. [7414].
22. Deeks J.J.H.J., Altman D.G. Analysing and presenting results. Cochrane handbook for systematic reviews of interventions 2006, John Wiley & Sons, Ltd., Chichester, United Kingdom, [ed 4.2.6, updated September 2006]. J.P. Higgins, S. Green (Eds.).
23. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(September (3)):177-188.
24. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(September):629-634. [7109].
25. McQuay H.J., Moore R.A. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997, 126(May (9)):712-720.
26. Smeeth L., Haines A., Ebrahim S. Numbers needed to treat derived from meta-analyses-sometimes informative, usually misleading. BMJ 1999, 318(June):1548-1551. [7197].
27. Altman D.G., Deeks J.J. Meta-analysis Simpson's paradox, and the number needed to treat. BMC Med Res Methodol 2002, 2:3.
28. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999, 354(November (9193)):1896-1900.
29. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27(March (8)):1227-1234.
30. Nishio M, Horai T, Kunitoh H, Ichinose Y, Nishiwaki Y, Hida T, et al., editors. Randomized, open-label, multicenter phase II study of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naive Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): JO19907. J Clin Oncol 2009; 27(15s) [Suppl. abstr 8036^].
31. Ichinose Y., Seto T., Kunitoh H., Horai T., Nishiwaki Y., Hida T., et al. Clinical outcomes of bevacizumab in combination with paclitaxel/carboplatin compared with paclitaxel/carboplatin alone in previously untreated Japanese patients with advanced non-squamous non-small-cell lung cancer (NSCLC). Eur J Cancer Suppl 2009, 7(September (2)):508.
32. D'Addario G., Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(May (Suppl. 4)):68-70.
33. Foster N.R., Qi Y., Shi Q., Krook J.E., Kugler J.W., Jett J.R., et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer 2010 October 19.
34. Crino L., Dansin E., Garrido P., Griesinger F., Laskin J., Pavlakis N., et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL MO19390): a phase 4 study. Lancet Oncol 2010, 11(August (8)):733-740.
35. Lynch TJ, Brahmer J, Fischbach N, Garst J, Kumar P, Spigel DR, et al., Editors. Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS). J Clin Oncol 2008;26 (May Suppl.) [abstr 8077].